TNFRSF10C抗体 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07246(TNFRSF10C Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07246(TNFRSF10C Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

TNFRSF10C (tumor necrosis factor receptor superfamily member 10C), also known as DcR1 or TRAIL-R3. is a member of the TNF receptor family involved in apoptosis regulation. It is a glycosylphosphatidylinositol (GPI)-anchored transmembrane protein lacking a functional intracellular death domain, distinguishing it from pro-apoptotic receptors like TNFRSF10A (TRAIL-R1) and TNFRSF10B (TRAIL-R2). TNFRSF10C binds to TRAIL (TNF-related apoptosis-inducing ligand) but cannot initiate apoptotic signaling, acting instead as a decoy receptor to modulate TRAIL-mediated cell death. Its expression is implicated in cancer progression, where it may protect tumor cells from immune surveillance by competing with death-signaling receptors.

Antibodies targeting TNFRSF10C are essential tools for studying its role in apoptosis resistance, immune evasion, and cancer biology. They enable detection of protein expression in tissues (e.g., via Western blot, immunohistochemistry) and functional studies to explore its dual role as either a tumor suppressor or promoter, depending on cellular context. Some therapeutic strategies investigate blocking TNFRSF10C to enhance TRAIL-induced apoptosis in malignancies, though clinical applications remain experimental. Research also focuses on its potential as a biomarker for cancer prognosis or therapeutic response. Challenges persist in clarifying its context-dependent mechanisms and reconciling contradictory findings across cancer types.